LSBCF (LakeShore Biopharma Co) EBIT: $-11.66 Mil (TTM As of Mar. 2025)


What is LakeShore Biopharma Co EBIT?

LakeShore Biopharma Co LSBCF EBIT is $-11.66 Mil as of Mar. 2025. The stock has 5 warning signs investors should review.

LakeShore Biopharma Co's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2025 was $-15.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LakeShore Biopharma Co's annualized ROC % for the quarter that ended in Mar. 2025 was -15.67%. LakeShore Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -27.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -19.50%.

LakeShore Biopharma Co  (OTCPK:LSBCF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LakeShore Biopharma Co's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=-21.842 * ( 1 - 1.77% )/( (133.461 + 140.384)/ 2 )
=-21.4553966/136.9225
=-15.67 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=202.462 - 62.01 - ( 6.991 - max(0, 103.176 - 120.454+6.991))
=133.461

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=188.661 - 45.868 - ( 3.874 - max(0, 113.77 - 116.179+3.874))
=140.384

Note: The Operating Income data used here is two times the semi-annual (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

LakeShore Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-31.33/( ( (63.584 + max(51.227, 0)) + (57.157 + max(52.337, 0)) )/ 2 )
=-31.33/( ( 114.811 + 109.494 )/ 2 )
=-31.33/112.1525
=-27.94 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(74.831 + 28.062 + 10.57) - (62.01 + 0.226 + 1.4210854715202E-14)
=51.227

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(69.099 + 31.395 + 11.691) - (45.868 + 0.201 + 13.779)
=52.337

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=-11.656/59.781
=-19.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co EBIT Related Terms

LakeShore Biopharma Co EBIT Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co EBIT Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
-22.22 -15.50 -16.47 -57.05 -11.75

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
EBIT Get a 7-Day Free Trial Premium Member Only -17.15 -22.25 -34.50 4.01 -15.67

LSBCF vs ACUT, PPCB, ENSC: EBIT Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBIT falls into.


LakeShore Biopharma Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-11.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-11.66 Mil mean?
LakeShore Biopharma Co (LSBCF) has a EBIT of $-11.66 Mil as of Mar. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LakeShore Biopharma Co.
Is LakeShore Biopharma Co's EBIT too high?
LakeShore Biopharma Co's current EBIT is $-11.66 Mil.
How does LakeShore Biopharma Co's EBIT compare to ACUT and PPCB?
LakeShore Biopharma Co's EBIT of $-11.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LakeShore Biopharma Co. LakeShore Biopharma Co's current EBIT is $-11.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current EBIT of $-11.66 Mil. The current EBIT is $-11.66 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current EBIT is $-11.66 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.